Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients

Frances Humby; Myles Lewis; Nandhini Ramamoorthi; Jason A. Hackney; Michael R. Barnes; Stefano Bombardieri; Audi Setiadi; Stephen Kelly; Fabiola Bene; Maria DiCicco; Sudeh Riahi; Vidalba Rocher; Nora Ng; Ilias Lazarou; Rebecca Hands; Désirée van der Heijde; Robert Landewé; Annette H M van der Helm–van Mil; Alberto Cauli; Iain B. McInnes; Christopher D. Buckley; Ernest Choy; Peter C. Taylor; Michael J. Townsend; Costantino Pitzalis

doi:10.1136/annrheumdis-2018-214539

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

We demonstrate at disease presentation, prior to pathology modulation by therapy, the presence of specific cellular/molecular synovial signatures that delineate disease severity/progression and therapeutic response and may pave the way to more precise definition of RA taxonomy, therapeutic targeting and improved outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Humby et al. (2019) studied this question.

synapsesocial.com/papers/69da2438a6045d71bfa3c2a3 https://doi.org/10.1136/annrheumdis-2018-214539

View Full Paper

Ask AI

Bookmark

Share

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients

Ask about this paper

Abstract

Discussion

Cite This Study

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading